NVAX stock trades in a wide range as Novavax works through Covid vaccine transition

Novavax Inc. (ISIN US6707721049) has seen NVAX stock trade in a wide range as the vaccine specialist navigates the post-pandemic Covid market and works to stabilize its revenue base with a leaner cost structure and new partnership income.

Revenue down from 2023 peak

In its most recent reported full year, Novavax generated total revenue of roughly $0.9 billion in 2024, down from about $1.0 billion in 2023 as the global Covid vaccination campaign shifted from mass programs to a more routine, seasonal market with lower volumes and prices in many regions.

Management has indicated that 2024 revenue was driven primarily by remaining Covid product sales, advance purchase agreement settlements, and certain contract adjustments, all of which are not expected to recur at the same scale in future years as the company transitions toward a more normalized commercial model.

Guidance targets at least $0.8 billion

For 2025, Novavax has guided investors to expect at least about $0.8 billion in total revenue, including a mix of Covid vaccine product sales, royalties, and other collaboration-related income. This outlook is below the pandemic-era peak but is intended to support a sustainable operating profile after multiple rounds of cost reductions.

The 2025 guidance compares with the roughly $0.9 billion achieved in 2024 and highlights the challenge of offsetting declining legacy Covid contract revenues with newer, more commercially driven demand in the United States, Europe, and other key markets.

Covid franchise remains core product

The company continues to focus commercially on its protein-based Covid vaccine as the core product line, aiming to serve individuals who prefer or require a non-mRNA option and to participate in seasonal booster campaigns in major markets.

NVAX stock and market context

NVAX stock on Nasdaq reflects this transition from a high-growth pandemic profile toward a smaller but recurring revenue base, with investors weighing 2025 revenue guidance of at least about $0.8 billion against the prior-year revenue of around $0.9 billion in 2024 and the steeper drop from the roughly $1.0 billion reported in 2023.